Scalper1 News
Biotech stocks are back near the top of IBD’s industry rankings amid strong earnings growth and promising new drugs. The group has rebounded to No. 4 out of the 197 industry groups that IBD tracks. That’s up from No. 72 just three weeks ago, according to Monday’s IBD. Gilead Pharmaceuticals (GILD) is among six stocks in the 345-member group with a best-possible 99 Composite Rating. The others are Regeneron Pharmaceuticals (REGN), Celgene (CELG), Scalper1 News
Scalper1 News